APEIRON Biologics Company
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for COVID-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.
Technology:
COVID
Headquarters:
Austria
Funding Status:
N/A
Investment Stage:
N/A
Founded Date:
N/A
Number Of Exists:
N/A
Employee Number:
N/A
Industry:
Vaccine/Drug
Investor Type:
N/A